PYC Therapeutics Gelecekteki Büyüme

Future kriter kontrolleri 1/6

PYC Therapeutics kazanç ve gelirin sırasıyla yıllık 34.7% ve 15.6% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 5.3% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde -28.5% olacağı tahmin edilmektedir.

Anahtar bilgiler

34.7%

Kazanç büyüme oranı

5.3%

EPS büyüme oranı

Biotechs kazanç büyümesi	15.3%
Gelir büyüme oranı	15.6%
Gelecekteki özkaynak getirisi	-28.4%
Analist kapsamı	Low
Son güncelleme	18 Nov 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Non-Executive Chair of the Board Alan Tribe Just Bought A Handful Of Shares In PYC Therapeutics Limited (ASX:PYC)

Feb 20

Have Insiders Been Selling PYC Therapeutics Limited (ASX:PYC) Shares?

Jan 26

What You Need To Know About PYC Therapeutics Limited's (ASX:PYC) Investor Composition

Dec 22

We Think PYC Therapeutics (ASX:PYC) Can Easily Afford To Drive Business Growth

Nov 17

Kazanç ve Gelir Büyüme Tahminleri

ASX:PYC - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (AUD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
6/30/2027	35	-13	-19	1	4
6/30/2026	35	-19	-37	-29	4
6/30/2025	9	-48	-39	-44	4
6/30/2024	22	-38	-39	-39	N/A
3/31/2024	22	-30	-29	-29	N/A
12/31/2023	21	-22	-20	-19	N/A
9/30/2023	19	-22	-22	-22	N/A
6/30/2023	16	-23	-25	-24	N/A
3/31/2023	15	-23	-26	-25	N/A
12/31/2022	14	-24	-26	-26	N/A
9/30/2022	15	-19	-24	-24	N/A
6/30/2022	16	-14	-22	-22	N/A
3/31/2022	13	-15	-18	-17	N/A
12/31/2021	9	-17	-14	-13	N/A
9/30/2021	6	-17	-13	-12	N/A
6/30/2021	3	-18	-12	-12	N/A
3/31/2021	3	-15	-11	-11	N/A
12/31/2020	2	-12	-10	-10	N/A
9/30/2020	2	-9	-8	-8	N/A
6/30/2020	2	-7	-6	-6	N/A
3/31/2020	1	-6	-6	-6	N/A
12/31/2019	0	-5	-6	-6	N/A
9/30/2019	0	-5	-6	-6	N/A
6/30/2019	N/A	-4	-6	-5	N/A
3/31/2019	0	-4	-4	-4	N/A
12/31/2018	0	-5	-3	-3	N/A
9/30/2018	0	-6	-5	-5	N/A
6/30/2018	0	-7	-7	-7	N/A
3/31/2018	0	-6	N/A	-5	N/A
12/31/2017	0	-5	N/A	-3	N/A
9/30/2017	1	-3	N/A	-3	N/A
6/30/2017	3	-2	N/A	-2	N/A
3/31/2017	3	-3	N/A	-4	N/A
12/31/2016	3	-4	N/A	-6	N/A
9/30/2016	1	-4	N/A	-5	N/A
6/30/2016	0	-4	N/A	-3	N/A
3/31/2016	0	-4	N/A	-2	N/A
12/31/2015	0	-4	N/A	-1	N/A
9/30/2015	0	-3	N/A	-2	N/A
6/30/2015	1	-3	N/A	-2	N/A
3/31/2015	1	-3	N/A	-3	N/A
12/31/2014	1	-3	N/A	-4	N/A
9/30/2014	1	-3	N/A	-4	N/A
6/30/2014	1	-3	N/A	-3	N/A
3/31/2014	1	-3	N/A	-3	N/A
12/31/2013	1	-3	N/A	-3	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: PYC önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: PYC önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: PYC önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: PYC şirketinin gelirinin (yıllık 15.6% ) Australian pazarından (yıllık 5.7% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: PYC şirketinin gelirinin (yıllık 15.6% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: PYC 3 yıl içinde kârsız olması bekleniyor.

PYC Therapeutics Gelecekteki Büyüme

Future kriter kontrolleri 1/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Price target increased by 8.2% to AU$0.33

Price target increased by 9.1% to AU$0.30

Price target decreased by 15% to AU$0.29

Forecast to breakeven in 2026

Recent updates

New minor risk - Market cap size

We're Hopeful That PYC Therapeutics (ASX:PYC) Will Use Its Cash Wisely

Price target increased by 8.2% to AU$0.33

PYC Therapeutics Limited, Annual General Meeting, Nov 13, 2024

Price target increased by 9.1% to AU$0.30

Insufficient new directors

New minor risk - Share price stability

New major risk - Revenue and earnings growth

Price target decreased by 15% to AU$0.29

PYC Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 74.657302 million.

Forecast to breakeven in 2026

Companies Like PYC Therapeutics (ASX:PYC) Are In A Position To Invest In Growth

PYC Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 74.657343 million.

New major risk - Financial position

Pyc Therapeutics Announces the Results of A Study Conducted in Human 3-Dimensional Models Derived from Patients with End-Stage Renal Failure Due to Autosomal Dominant Polycystic Kidney Disease

Is PYC Therapeutics (ASX:PYC) In A Good Position To Deliver On Growth Plans?

PYC Therapeutics Limited, Annual General Meeting, Nov 24, 2023

New minor risk - Financial data availability

PYC Therapeutics Limited Announces US FDA Designates PYC's Lead as a Fast Track Development Program

New minor risk - Share price stability

We Think PYC Therapeutics (ASX:PYC) Needs To Drive Business Growth Carefully

Non-Executive Chair of the Board recently bought AU$85k worth of stock

PYC Therapeutics Limited, Annual General Meeting, Jul 05, 2023

Pyc Appoints Andrew Taylor as Joint Company Secretary

PYC Therapeutics Limited Announces the Submission of Investigational New Drug Application with the US Food and Drug Administration

Here's Why We're Watching PYC Therapeutics' (ASX:PYC) Cash Burn Situation

High number of new and inexperienced directors

PYC Therapeutics Limited Announces Successful Toxicology Studies Pave Way for Human Trials

PYC Therapeutics Limited, Annual General Meeting, Nov 23, 2022

PYC Therapeutics Limited Announces Central Nervous System Drug Program Added to PYC Pipeline

Non-Executive Chair of the Board recently bought AU$103k worth of stock

PYC Therapeutics Limited Announces Exemplary PK Study Results Move RP11 Program Closer to First in Human Trials

High number of new and inexperienced directors

Companies Like PYC Therapeutics (ASX:PYC) Are In A Position To Invest In Growth

PYC Therapeutics Limited Enters into the Next Phase of Preclinical Development for VP-001

PYC Therapeutics Announces Comprehensive Preclinical Results Demonstrating VP-002 Program's Potential as the First Disease Modifying Therapy for Autosomal Dominant Optic Atrophy

CEO & Director exercised options to buy AU$1.6m worth of stock.

PYC Therapeutics to Develop A New Generation of RNA Therapeutics

PYC Therapeutics Limited Announces Second Investigational Drug Candidate Restores the Levels of the Target Protein Towards Normal in Models Derived from Patients with the Indicated Disease ­ Autosomal Dominant Optic Atrophy

We're Not Very Worried About PYC Therapeutics' (ASX:PYC) Cash Burn Rate

PYC Therapeutics Limited Appoints Michael Rosenblatt, MD, to Its Board of Directors

PYC's Lead Investigational Drug, VP-001, Demonstrates Another Key Functional Improvement in Patient-Derived Models - a First for Any Rp11 Treatment to-Date

PYC Therapeutics Names Glenn Noronha as Chief Development Officer

Non-Executive Chair of the Board Alan Tribe Just Bought A Handful Of Shares In PYC Therapeutics Limited (ASX:PYC)

Non-Executive Chair of the Board recently bought AU$81k worth of stock

Have Insiders Been Selling PYC Therapeutics Limited (ASX:PYC) Shares?

What You Need To Know About PYC Therapeutics Limited's (ASX:PYC) Investor Composition

PYC Therapeutics Limited Announces Visual Evidence of Lead Drugs Efficacy

PYC Therapeutics Limited Appoints Sahm Nasseri as CEO of Us Operations and as Director of the Board

We Think PYC Therapeutics (ASX:PYC) Can Easily Afford To Drive Business Growth

PYC Therapeutics Announces to Developing New Treatments for Severe Unmet Patient Needs

Doug Huey Not to Seek Re Election At PYC Therapeutics Limited

PYC Therapeutics Limited Develops New Treatments for Severe Unmet Patient Needs

PYC Therapeutics Limited Files for Intellectual Property Protection for the New Drug Candidate

PYC Therapeutics Limited Announces CEO Changes

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin

PYC Therapeutics Limited Announces Second Investigational Drug Candidate Restores the Levels of the Target Protein Towards Normal in Models Derived from Patients with the Indicated Disease Autosomal Dominant Optic Atrophy